News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

A three-drug therapy targeting breast cancer could double the amount of time patients live without the disease progressing, a trial has found. Researchers praised the “huge breakthrough” as ...

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.

A powerful, three-drug therapy ... positive breast cancer. "The results show that inavolisib in combination with palbociclib and fulvestrant significantly improves progression-free survival ...

Mei Wei, MD, an oncologist specializing in breast ... CDK4/6 inhibitors plus aromatase inhibitors as the first line of therapy has significantly improved the PFS and the overall survival as ...

Neoadjuvant therapy is the therapy you receive before your main treatment or surgery. Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an ...

A powerful three-drug therapy for aggressive ... of PIK3CA mutant HR-positive breast cancer. The results show that inavolisib in combination with palbociclib and fulvestrant significantly improves ...

A three-drug combination targeting aggressive advanced breast cancer ... the hormone therapy fulvestrant. The placebo group, which included 164 patients, were given a placebo plus palbociclib ...